Fred Eshelman - Founding Chairman @ Furiex Pharmaceuticals

Start Free Trial

Pricing

Overview

Number of Portfolio Companies

Number of Exits

Unlock for free

Primary Job Title Founding Chairman
Primary Organization
Furiex Pharmaceuticals

Location Wilmington, North Carolina, United States
Regions East Coast, Southern US
Gender Male

Investor Type
obfuscated
obfuscation
Investor Stage
obfuscated
obfuscation
Number of Exits
obfuscated
obfuscation

LinkedIn View on LinkedIn

Fred Eshelman is the Strategic Advisor of Paradigm Therapeutics. He is the Pharm.D., is Furiex's founding chairman. He was the founder and executive chairman of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) prior to its sale to private equity.

Personal Investments

Number of Investments

Fred Eshelman

has made

investments. Their latest investment was

Series A - Breakthru Medicine

obfuscation

, when

Breakthru Medicine

raised

obfuscation

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Breakthru Medicine	—	Series A - Breakthru Medicine	obfuscated obfuscation
obfuscated obfuscation	Furiex Pharmaceuticals	No	Post-IPO Debt - Furiex Pharmaceuticals	obfuscated obfuscation

Partner Investments

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Incyclix Bio	Eshelman Ventures	Yes	Series B - Incyclix Bio	obfuscated obfuscation
obfuscated obfuscation	Jupiter BioVentures	Eshelman Ventures	—	Venture Round - Jupiter BioVentures	obfuscated obfuscation
obfuscated obfuscation	Incyclix Bio	Eshelman Ventures	—	Series B - Incyclix Bio	obfuscated obfuscation
obfuscated obfuscation	Aravive Biologics	Eshelman Ventures	Yes	Post-IPO Equity - Aravive Biologics	obfuscated obfuscation
obfuscated obfuscation	Innocrin Pharmaceuticals	Eshelman Ventures	Yes	Series D - Innocrin Pharmaceuticals	obfuscated obfuscation
obfuscated obfuscation	G1 Therapeutics	Eshelman Ventures	Yes	Series B - G1 Therapeutics	obfuscated obfuscation

Exits

Number of Exits

Unlock for free

Fred Eshelman

has

obfuscation

exit -

Furiex Pharmaceuticals

Fred Eshelman

has

obfuscation

exits. Their most notable exits are

Furiex Pharmaceuticals

Furiex Pharmaceuticals Furiex Pharmaceuticals is a drug development collaboration company focused on improving the value of partnered drug programs.

Jobs

Number of Current Jobs

Number of Past Jobs

Fred Eshelman

has

current jobs including

Founding Chairman

Furiex Pharmaceuticals

Director

Accelerator Corp.

, and

Founder

Eshelman Ventures

. Additionally,

Fred Eshelman

has had

past job as the

Founder and Executive Chairman

PPD clinical research business of Thermo Fisher Scientific

Furiex Pharmaceuticals Founding Chairman
Accelerator Corp. Director
Eshelman Ventures Founder
PPD clinical research business of Thermo Fisher Scientific Founder

Organization Name	Title At Company	Start Date	End Date
PPD clinical research business of Thermo Fisher Scientific	Founder and Executive Chairman	—	—

Board and Advisor Roles

Number of Current Board & Advisor Roles

Fred Eshelman

holds

board and advisor roles including

Board Member

Breakthru Medicine

Strategic Advisor

Paradigm Therapeutics

, and

Board Member

Jupiter BioVentures

Breakthru Medicine Board MemberJan 2026
Paradigm Therapeutics Strategic AdvisorMay 6, 2025
Jupiter BioVentures Board MemberNov 19, 2024
Phoenix Molecular Designs Board MemberMar 2024
Aravive Biologics Chairman

Related Hubs

Hub Name	CB Rank (Hub)
Health Diagnostics Companies that Exited	13,595
Companies That Exited in 2010	8,777
Closed North Carolina Companies	23,731
Acquired North Carolina Companies	7,700
Closed East Coast Biotechnology Companies	28,892
Closed United States Biotechnology Companies	13,019
North Carolina Companies that Exited	7,244
Acquired Biotechnology Companies	4,200
Closed Biotechnology Companies	15,037
Companies that Went Public in 2010	17,083

Recent News and Activity

Number of News Articles

Funding Round•

Jan 29, 2026

Breakthru Medicine raised

obfuscation

from Dave Morehead and 2 other investors

Discover more funding rounds

News•

Dec 8, 2022